sitemap
waves
 

News Release

Second Tetrodotoxin Export Order

Date: Mar 06, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that it has received its second export order for tetrodotoxin (TTX).

This second order of TTX has been received from a university institute of pharmacology in Europe.

This order further validates our unique market niche in supplying industry with high quality TTX to address sodium channel research in neuroscience.

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.

Home | News | Corporate | Products | Investors | Licensing | Contact |

 
Copyright WEX Pharmaceuticals Inc. All rights reserved.
Privacy Policy | Disclaimer
Website designed by Attention Media.